Results 241 to 250 of about 1,505,630 (287)

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

A strategic approach to managing Immune Effector Cell-Associated Hematotoxicity (ICAHT) during chimeric antigen receptor T-cell therapy. [PDF]

Blood Res
Yoon SE.
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Kidney Med
Shivaraj K, Mamlouk O, Tchakarov A, Patel K, Abudayyeh A.   +4 more
europepmc   +1 more source

Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity. [PDF]

Adv Sci (Weinh)
Zhang X, Aimaiti G, Guan Y, Sha Y, Zhou W, Shen J, Zhao B, Yuan WE.   +7 more
europepmc   +1 more source

Innate immune cells in chimeric antigen receptor therapy. [PDF]

Mol Ther
Jassaud M, Ziane-Chaouche L, Duhamel M, Salzet M.   +3 more
europepmc   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System. [PDF]

Immun Inflamm Dis
Yao SY, Du MQ, Yang H, Zeng QM, Zhou H, Zhang X, Kazuo S, Liu J, Lin LX, Kang XH, Jiang DY, Peng Y.   +11 more
europepmc   +1 more source

Chimeric antigen receptor-based cell therapy for treating urological tumors. [PDF]

Curr Urol
Tang H, Guo L, Zhang W, Tang D.
europepmc   +1 more source

A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model.

Exp Hematol
Fernández N, Petazzi P, Mulens-Arias V, Pérez LG, Menéndez P, Díaz VM.   +5 more
europepmc   +1 more source